Last reviewed · How we verify
Compazine
At a glance
| Generic name | Compazine |
|---|---|
| Also known as | Compro, prochlorperazine |
| Sponsor | University of Michigan Rogel Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- Intranasal Ketorolac Trial (PHASE2)
- Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy (PHASE3)
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
- Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (PHASE3)
- Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo. (PHASE3)
- Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |